C07D 473/26
Heterocyclic compounds containing purine ring systems: with an oxygen, sulphur, or nitrogen
Official title: with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
C07D473/26 (Heterocyclic compounds containing purine ring systems: with an oxygen, sulphur, or nitrogen) appears on 1,269 US grants and 1,522 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,269
- Published applications
- 1,522
- Assignees
- 773
- Inventors
- 3,977
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 5 | 0 |
| 1979 | 4 | 0 |
| 1980 | 10 | 0 |
| 1981 | 4 | 0 |
| 1982 | 5 | 0 |
| 1983 | 6 | 0 |
| 1984 | 5 | 0 |
| 1985 | 5 | 0 |
| 1986 | 6 | 0 |
| 1987 | 4 | 0 |
| 1988 | 6 | 0 |
| 1989 | 14 | 0 |
| 1990 | 6 | 0 |
| 1991 | 15 | 0 |
| 1992 | 12 | 0 |
| 1993 | 15 | 0 |
| 1994 | 10 | 0 |
| 1995 | 7 | 0 |
| 1996 | 9 | 0 |
| 1997 | 20 | 0 |
| 1998 | 8 | 0 |
| 1999 | 19 | 0 |
| 2000 | 26 | 0 |
| 2001 | 22 | 2 |
| 2002 | 24 | 21 |
| 2003 | 26 | 35 |
| 2004 | 22 | 44 |
| 2005 | 19 | 33 |
| 2006 | 20 | 47 |
| 2007 | 20 | 45 |
| 2008 | 22 | 46 |
| 2009 | 32 | 61 |
| 2010 | 24 | 65 |
| 2011 | 28 | 71 |
| 2012 | 48 | 72 |
| 2013 | 53 | 80 |
| 2014 | 68 | 89 |
| 2015 | 78 | 70 |
| 2016 | 67 | 100 |
| 2017 | 68 | 82 |
| 2018 | 76 | 94 |
| 2019 | 82 | 97 |
| 2020 | 68 | 62 |
| 2021 | 35 | 57 |
| 2022 | 42 | 52 |
| 2023 | 18 | 64 |
| 2024 | 26 | 39 |
| 2025 | 32 | 57 |
| 2026 | 24 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- PIKfyve kinase inhibitors22 Sep 2026US 12,741,960 B2Acurastem Incorporated
- Method for labeling nucleic acid11 Aug 2026US 12,703,881 B2Cambridge Enterprise Limited
- Adenosine analog and its use in regulating the circadian clock30 Jun 2026US 12,667,584 B2National Institute of Biological Sciences, Beijing
- POLQ inhibitors16 Jun 2026US 12,653,828 B2AstraZeneca AB
- Adenosine analogs for the treatment of disease9 Jun 2026US 12,649,740 B2Biointervene, Inc.
- Prmt inhibitor compounds and the uses thereof8 Oct 2026US 2026/0306527 A1Purdue Research Foundation
- Substituted pyridinone compounds and uses thereof1 Oct 2026US 2026/0294879 A1Pfizer Inc.
- Adenosine analog and its use in regulating the circadian clock1 Oct 2026US 2026/0294952 A1National Institute of Biological Sciences, Beijing
- Polq inhibitors24 Sep 2026US 2026/0284059 A1AstraZeneca AB
- Btk degrading compounds17 Sep 2026US 2026/0274849 A1Beijing neoX Biotech Limited
Most cited
By later US patents
- Pyrrolidine-containing monomers and oligomers675US 5,519,134 AIsis Pharmaceuticals, Inc. · 1996
- Chemical amplification based on fluid partitioning573US 7,041,481 B2The Regents of the University of California · 2006
- Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same547US 5,130,302 ABoron Bilogicals, Inc. · 1992
- Acyclic nucleoside analogs and oligonucleotide sequences containing them413US 5,576,427 ASterling Winthrop Inc. · 1996
- Method for deuteration of a heterocyclic ring304US 7,517,990 B2Wako Pure Chemical Industries, Ltd. · 2009